These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 17012103
1. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. Espié M, Mares P, de Reilhac P, Chevallier T, Daurès JP. Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103 [Abstract] [Full Text] [Related]
2. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Gynecol Endocrinol; 2007 Jul; 23(7):391-7. PubMed ID: 17701770 [Abstract] [Full Text] [Related]
3. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, Sinn P, Bastert G, Sohn C. Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414 [Abstract] [Full Text] [Related]
4. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Olsson HL, Ingvar C, Bladström A. Cancer; 2003 Mar 15; 97(6):1387-92. PubMed ID: 12627501 [Abstract] [Full Text] [Related]
5. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy). Tzingounis V, Cardamakis E, Ginopoulos P, Argiropoulos G. Anticancer Res; 1996 Mar 15; 16(6C):3997-4000. PubMed ID: 9042326 [Abstract] [Full Text] [Related]
6. Coronary heart disease and HRT in France: MISSION study prospective phase results. Mares P, Chevallier T, Micheletti MC, Daures JP, Postruznik D, De Reilhac P. Gynecol Endocrinol; 2008 Dec 15; 24(12):696-700. PubMed ID: 19172539 [Abstract] [Full Text] [Related]
7. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. Nozaki M, Koera K, Nagata H, Nakano H. J Obstet Gynaecol Res; 2004 Aug 15; 30(4):297-302. PubMed ID: 15238106 [Abstract] [Full Text] [Related]
8. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer. Alvarez-Vasquez RB, Axelrod D, Frenkel K, Newman MC, Sepkovic DW, Bradlow HL, Zumoff B. Horm Metab Res; 2003 Jun 15; 35(6):358-61. PubMed ID: 12920658 [Abstract] [Full Text] [Related]
9. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA. J Clin Oncol; 2003 Dec 01; 21(23):4314-21. PubMed ID: 14645420 [Abstract] [Full Text] [Related]
10. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R. Cancer Epidemiol Biomarkers Prev; 2003 Nov 01; 12(11 Pt 1):1175-81. PubMed ID: 14652277 [Abstract] [Full Text] [Related]
11. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Ursic-Vrscaj M, Bebar S. Eur J Surg Oncol; 1999 Apr 01; 25(2):146-51. PubMed ID: 10218456 [Abstract] [Full Text] [Related]
12. Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women. Cerne JZ, Ferk P, Leskosek B, Gersak K. Climacteric; 2011 Aug 01; 14(4):458-63. PubMed ID: 21294673 [Abstract] [Full Text] [Related]
13. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Arch Intern Med; 2006 Jul 24; 166(14):1483-9. PubMed ID: 16864758 [Abstract] [Full Text] [Related]
14. [Estrogen replacement therapy and breast cancer]. Bakken K, Alsaker E, Eggen AE, Lund E. Tidsskr Nor Laegeforen; 2005 Feb 03; 125(3):282-5. PubMed ID: 15702147 [Abstract] [Full Text] [Related]
15. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Strom BL, Schinnar R, Weber AL, Bunin G, Berlin JA, Baumgarten M, DeMichele A, Rubin SC, Berlin M, Troxel AB, Rebbeck TR. Am J Epidemiol; 2006 Oct 15; 164(8):775-86. PubMed ID: 16997897 [Abstract] [Full Text] [Related]
16. Impact of hormone replacement therapy on the histologic subtype of breast cancer. Zanetti-Dällenbach RA, Krause EM, Lapaire O, Gueth U, Holzgreve W, Wight E. Arch Gynecol Obstet; 2008 Nov 15; 278(5):443-9. PubMed ID: 18335229 [Abstract] [Full Text] [Related]
17. Breast cancer risk in the WHI study: the problem of obesity. Kuhl H. Maturitas; 2005 May 16; 51(1):83-97. PubMed ID: 15883113 [Abstract] [Full Text] [Related]
18. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Genazzani AR, Gambacciani M. Gynecol Endocrinol; 2006 Mar 16; 22(3):145-50. PubMed ID: 16835076 [Abstract] [Full Text] [Related]
19. Hormone replacement therapy and breast density changes. Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, de Palacios PI, Ragavan VV. Climacteric; 2005 Jun 16; 8(2):185-92. PubMed ID: 16096175 [Abstract] [Full Text] [Related]
20. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Cancer Epidemiol Biomarkers Prev; 2005 Sep 16; 14(9):2137-42. PubMed ID: 16172222 [Abstract] [Full Text] [Related] Page: [Next] [New Search]